Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis
Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis
复制标题
DOI：
10.1016/j.amjoto.2006.06.016
复制
发表时间：
2007-03-01
影响因子：
2.5
通讯作者：
Torres, Arturo
中科院分区：
文献类型：
--
作者：
Arrieta, Jose R.;Galgano, Alejandro S.;Torres, Arturo
目的：本研究的目的是比较莫西沙星与阿莫西林/克拉维酸治疗成人急性细菌性鼻窦炎的疗效和安全性。材料和方法：在一项前瞻性开放研究中，来自拉丁美洲国家的575名患者随机接受口服莫西沙星400mg，每日一次，连续7天，或口服阿莫西林/克拉维酸500/ 125mg，每日3次，连续10天。结果：治疗结束后7 ~ 14天，莫西沙星组的临床成功率为93.4%，与阿莫西林/克拉维酸组（92.7%）相似。莫西沙星组（96.5%）和阿莫西林/克拉维酸组（96.7%）记录的细菌学根除和推测的根除率也相似。莫西沙星组32.2%的患者出现药物相关不良事件，阿莫西林/克拉维酸组29.7%的患者出现药物相关不良事件。莫西沙星组有10例患者因不良事件而停药，阿莫西林/克拉维酸组有6例患者因不良事件而停药。结论：总体而言，在临床和细菌学反应方面，莫西沙星与阿莫西林/克拉维酸治疗成人急性细菌性鼻窦炎的疗效相当。(C) 2007爱思唯尔公司版权所有。
Purpose: The aim of this study was to compare the efficacy and safety of moxifloxacin with that of amoxicillin/clavulanate for the treatment of acute bacterial sinusitis in adults.Materials and methods: Five hundred seventy-five patients from Latin American countries were randomized to receive oral moxifloxacin 400 mg once daily for 7 days, or oral amoxicillin/ clavulanate 500/125 mg 3 times daily for 10 days, in a prospective, open study.Results: At the test-of-cure visit (7-14 days after the end of therapy), the clinical success rate in the moxifloxacin group was 93.4% similar to that in the amoxicillin/clavulanate group (92.7%). Documented bacteriological eradication plus presumed eradication rates in the moxifloxacin (96.5%) and the amoxicillin/clavulanate (96.7%) groups were also similar. Drug-related adverse events were recorded in 32.2% of patients in the moxifloxacin group and 29.7% in the amoxicillin/clavulanate group. Patient discontinuation in the trial due to adverse events occurred for 10 patients in the moxifloxacin group and 6 in the amoxicillin/clavulanate group.Conclusions: Overall, in terms of clinical and bacteriological response, moxifloxacin was equivalent to amoxicillin/clavulanate for the treatment of acute bacterial sinusitis in adults. (C) 2007 Elsevier Inc. All rights reserved.